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Abstract
Background: Chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis (MBL) with (MBLhi) or without (MBLlo)
absolute B-lymphocytosis precedes most CLL cases,the specific determinants for malignant progression remaining
unknown.
Methodology/Principal Findings: For this purpose, simultaneous iFISH and molecular analysis of well-established
cytogenetic alterations of chromosomes 11, 12, 13, 14 and 17 together with the pattern of rearrangement of the IGHV genes
were performed in CLL-like cells from MBL and CLL cases. Our results based on 78 CLL-like MBL and 117 CLL clones from 166
subjects living in the same geographical area, show the existence of three major groups of clones with distinct but partially
overlapping patterns of IGHV gene usage, IGHV mutational status and cytogenetic alterations. These included a group
enriched in MBLlo clones expressing specific IGHV subgroups (e.g. VH3-23) with no or isolated good-prognosis cytogenetic
alterations, a second group which mainly consisted of clinical MBLhi and advanced stage CLL with a skewed but different
CLL-associated IGHV gene repertoire (e.g. VH1-69), frequently associated with complex karyotypes and poor-prognosis
cytogenetic alterations, and a third group of clones with intermediate features, with prevalence of mutated IGHV genes, and
higher numbers of del(13q)+ clonal B-cells.
Conclusions/Significance: These findings suggest that the specific IGHV repertoire and IGHV mutational status of CLL-like
B-cell clones may modulate the type of cytogenetic alterations acquired, their rate of acquisition and/or potentially also
their clinical consequences. Further long-term follow-up studies investigating the IGHV gene repertoire of MBLlo clones in
distinct geographic areas and microenvironments are required to confirm our findings and shed light on the potential role
of some antigen-binding BCR specificities contributing to clonal evolution.
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Introduction
Monoclonal B lymphocytosis (MBL) is defined by the presence
of a low to moderate expansion of circulating clonal B
lymphocytes (,56109/L) –most frequently resembling the phe-
notype of chronic lymphocytic leukemia (CLL) cells (CLL-like
cells)– in otherwise healthy adults, in the absence of symptoms and
signs of an underlying chronic lymphoid malignancy [1,2]. Recent
multiparameter flow cytometry studies have demonstrated that
CLL-like MBL clones can be found in a significant proportion of
healthy adults over 40 years. Their frequency ranges from 3.5% to
around 12% of the general population, and between 13% to 18%
of first-degree relatives of CLL patients, depending on the
sensitivity of the technique [3]. Although in most CLL-like MBL
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cases, MBL clones are associated with a stable and indolent clinical
course, a small proportion of cases presenting with lymphocytosis
will eventually progress to CLL [1,4]. On the other hand, it has
been shown that virtually every CLL is preceded by an MBL,
which may have remained stable for variable periods of time [5].
Identification and full characterization of the phenotypic and
genetic features of CLL-like MBL cells in the absence (MBLlo) and
presence (MBLhi) of an absolute B-lymphocytosis, versus CLL
cells, may provide insight into the key mechanisms and events
involved in the expansion of the MBL clones and their
transformation to CLL, thereby contributing to a better under-
standing of the natural history of the disease.
Previous studies have shown that MBLhi clones may display the
typical spectrum of chromosomal alterations observed in CLL, e.g.
del(13q), trisomy 12, del(11q) and even del(17p); conversely,
MBLlo B-cells appear to more frequently carry normal karyotypes
and to a lesser extent, isolated del(13q14.3) or trisomy 12, in the
absence of chromosomal alterations associated to poor prognosis
CLL, such as del(17p13) and del(11q22) [6]. These observations
suggest that MBLlo, MBLhi and CLL clones could be different
stages in the spectrum from reactive MBL B-cells to CLL requiring
therapy. Despite this, analysis of the pattern of usage of the
immunoglobulin heavy chain variable region (IGHV) gene in both
MBLhi and CLL cases showed that it is not random. Accordingly,
a predominant usage of specific IGHV subgroups has been
reported for both MBLhi clones and mutated CLL cells (e.g. the
IGHV3-23 and IGHV4-34) as well as for unmutated CLL
(e.g.IGHV1-69) [7]. In turn, very preliminary studies [8] indicate
that MBLlo clones rarely use the IGHV4-34 subgroup, while they
may display a higher frequency of IGHV4-59/61 B-cell receptor
(BCR) genes, which are rarely used in CLL [8].
Here, we investigated for the first time the potential existence of
unique cytogenetic profiles associated with specific IGHV
repertoires that could be associated with an increased risk of
progression from MBLlo to MBLhi and CLL. Our results, based on
a series of 78 MBL and 117 CLL clones from a total of 166
subjects from the same geographical area, suggest the existence of
distinct but partially overlapping molecular and cytogenetic
profiles among MBLlo, MBLhi and CLL cases.
Materials and Methods
Patients and Samples
A total of 166 subjects presenting one or more CLL-like MBL
and/or CLL clonal B-cell populations were included in this study:
15 cases (9%) corresponded to healthy individuals with MBLlo –
,200 clonal B-cells/mL in peripheral blood (PB); 5 males and 10
females; mean age of 68613 years; range: 49–84 years, –33 (20%)
were MBLhi –$200 and,5,000 clonal CLL-like B-cells/mL of PB
– (20 males and 13 females; mean age of 72612 years; range: 37–
89 years), –114 (69%) had newly-diagnosed untreated CLL (66
males and 48 females; mean age of 70613 years; range: 35–89
years) and 4 (2%) had other B-cell lymphoproliferative disorders
(B-CLPD) with coexistence of one or two CLL-like MBL B-cell
population(s). From the 33 MBLhi cases, 20 (61%) showed clinical
MBL (.2,000 clonal B-cells/ml of PB). Individuals corresponded
to consecutive MBL and CLL subjects from Salamanca (Spain)
and Coimbra (Portugal) in the western area of the Iberian
Peninsula.
PB samples were obtained from each subject after written
informed consent was given, and the study was approved by the
local ethics committees of the two participating centres (University
Hospital of Salamanca and Histocompatibility Centre of Coim-
bra). Diagnosis of MBL and CLL was based on the World Health
Organization (WHO) 2008 criteria [9]. Clinical staging of CLL
subjects according to Binet classification [9] was collected
retrospectively; 46/77 (60%) CLL cases were diagnosed as stage
A and the remaining cases (31/77, 40%) as stage B/C. Overall,
37/166 subjects (22%) showed co-existence of two or three
phenotypically different aberrant B-cell populations (multiclonal
cases; 25 males and 12 females with a mean age of 7668 years;
range: 57–89 years), while the remaining 129 individuals showed
one single phenotypically aberrant monoclonal B-cell population
(monoclonal cases; 69 males and 60 females with a mean age of
68612 years; range: 35–89 years). In 26/37 multiclonal cases, all
different B-cell populations showed a typical CLL-like phenotype,
while in the remaining 11 cases only one B-cell population
displayed a typical CLL-like phenotype co-existing with popula-
tion(s) phenotypically compatible with other B-CLPD [10]. For
this study, analysis was focused only on those aberrant B-cell
populations displaying a typical CLL-like and CLL phenotype
(n = 195 B-cell clones). The distribution of all CLL-like and CLL
clonal populations analyzed in the distinct diagnostic categories
was as follows: 27 corresponded to CLL-like MBLlo, 51 to CLL-
like MBLhi and 117 to CLL (Table 1).
Immunophenotypic Analyses
Immunophenotypic studies were performed on erythrocyte-
lysed whole PB samples according to procedures previously
described in detail [11]. PB white blood cells (WBC) were
systematically stained with the monoclonal antibody (MAb)
combinations detailed in Table S1. All cases showed a clonal
(imbalanced SmIgk:SmIgl ratio of .3:1 or ,1:3) and/or an
aberrant CD5+CLL-like B-cell population, as reported elsewhere
[12] (see Materials and Methods S1).
Data acquisition was performed in two steps on a FACSCanto
II flow cytometer – Becton-Dickinson Biosciences –(BD, San Jose´,
CA, USA) using the FACSDiva software (V6.1; BD): first,
information about 16105 events corresponding to the whole
sample cellularity was stored; in the second step, information was
stored exclusively for CD19+ and/or CD20+gated events,
contained in a minimum of 56106 leucocytes/tube. Instrument
setup, calibration and daily monitoring were performed according
to well-established protocols [13] (see Materials and Methods S1).
For data analysis, the InfinicytTM software (Cytognos SL,
Salamanca, Spain), was used. The minimum number of clustered
events required to define a B-cell population was of 50 cells.
Fluorescence-activated Cell Sorting (FACS) Purification of
B-cell Populations (FACSorting)
For all individuals studied, each CLL-like CD5+ B-cell
population identified was purified in a FACSAria III flow
cytometer (BD). In those samples with more than one aberrant
B-cell population (n = 37), discrimination among them was based
on their distinct patterns of expression for$1 of the B-cell markers
analyzed, as described elsewhere [11]. The clonal nature of each
FACS-purified B-cell population (purity: 98%60.8%) was assessed
by both cytogenetic and molecular techniques, as described below.
Cytogenetic and Molecular Studies
The presence of the most common cytogenetic abnormalities
associated with CLL was investigated by multicolour interphase
fluorescence in situ hybridization (iFISH) on slides containing
FACS-purified and fixed aberrant B-cells, as previously described
[14] (see Materials and Methods S1 for further details).
Analysis of the patterns of rearrangement of the IGHV genes
was performed for each FACS-purified CLL and CLL-like B-cell
IGHV and iFISH Patterns in MBL vs. CLL
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population. Genomic DNA preparation, PCR amplification,
sequencing and analysis of V, (D), J genes were performed
following well-established protocols [15,16] (see Materials and
Methods S1 for more detailed information).
Forward and reverse sequences were aligned into a single
resolved sequence and then aligned with germline sequences using
the IMGT database and tools (http://imgt.cines.fr). For MBLlo
clones, whole genomic amplification (WGA) was performed prior
to the analysis, using the RepligR UltraFast Mini kit (Qiagen,
Valencia, CA) as per the recommendations of the manufacturer.
For each clonal B-cell population, only in-frame rearrangements
were evaluated. Sequences containing .2% deviation from the
germline sequence were considered as being somatically mutated.
Those MBLlo cases showing more than one productive rearrange-
ment corresponding to different IGHV genes within each purified
CLL-like B-cell population were excluded from this study, because
in such cases we could not establish the precise association
between each IGHV gene and the underlying cytogenetic
alterations detected.
Analysis of CLL-associated NOTCH1 mutations [17] was
performed via PCR of previously amplified genomic DNA from
each FACS-purified CLL-like B-cell population for a total of 70
clones (5 MBLlo, 14 MBLhi and 51 CLL clones).
Statistical Methods
Conventional descriptive and comparative statistics –the non-
parametric Kruskal-Wallis and Mann-Whitney U tests (for
continuous variables), or the Pearson’s x2 and Fisher exact tests
(for categorical variables)–were performed using the SPSS software
program (SPSS 15.0 Inc. Chicago, IL). P values ,0.05 were
considered to be associated with statistical significance.
For multivariate comparisons among MBLlo, MBLhi and CLL
clones, based on the count of clonal B cells/mL and the percentage
of aberrant/clonal cells carrying the different cytogenetic profiles,
principal component analysis (PCA) was applied, and graphically
visualized with the 3D Automated Population Separator (APS)
view – Principal Component 1 (PC1) vs PC2 vs PC3– of the
InfinicytTM software (Cytognos SL, Salamanca, Spain). As
previously described in detail, in this APS view, each axis of a
plot is represented by a different PC as a linear combination of
parameters with distinct statistical weights [18].
For the assignment of MBLlo, MBLhi and CLL clones to
different groups, the size of the clone and the percentage of altered
cells for each cytogenetic abnormality were the continuous
variables included in the PCA-based assay performed with the
Infinicyt softwareTM, while IGHV gene usage, IGHV mutational
status and clinical staging of CLL subjects according to the Binet
classification were treated as categorical variables, used only for
labelling the different clones within each group, after applying the
PCA.
Results
Overall Size and BCR Features of CLL-like MBL and CLL B-
cell Clones
The median relative percentage and absolute count of CLL-like
and CLL B-cells progressively increased from MBLlo (0.6% and 20
cells/ml), to MBLhi (14% and 2,000 cells/ml) and CLL clones (57%
and 17,400 cells/ml) (P,0.0001) (Table 2).
Of note, around half of all MBLlo and MBLhi cell populations
(52% and 51%, respectively) derived from multiclonal cases,
whereas only 22% of CLL clones were identified in multiclonal
cases (P#0.03; Table 2). In addition, CLL clones less frequently
showed mutated IGHV genes (53%) compared to both MBLhi
(73%) and MBLlo (67%) clones (P#0.02) (Table 2).
Cytogenetic Features and NOTCH1 Mutation in CLL-like
MBL and CLL B-cell Clones
Overall, MBLlo B-cell clones showed a significantly lower
frequency of genetic alterations associated with CLL (33%) than
MBLhi (51%) and CLL (62%) B-cells (P#0.02) (Table 3).
Furthermore, only a small proportion of MBLlo (7%) and MBLhi
clones (14%) showed coexistence of $2 cytogenetic alterations,
while this was found in 33% of all CLL clones (P#0.04).
Regarding each specific cytogenetic/molecular alteration, a
tendency towards a greater frequency of del(13q) and trisomy 12
was observed from MBLlo to MBLhi and CLL clones, although
differences only reached statistical significance for the frequency of
del(13q14) involving the RB1 gene (P= 0.04). In addition, presence
of t(14q32) and del(11q22.3) were exclusively found among MBLhi
and CLL, while del(17p), del(11q23) and NOTCH1 mutations were
only present in CLL clones (Table 3). Of note, among the
cytogenetically altered clones, no significant differences were
observed in the percentage of altered cells, except for a greater
proportion of B-cells with trisomy 12 among both MBLhi and CLL
vs MBLlo B-cell clones (P#0.04) (Table 3).
Table 1. Distribution of subjects included in the study and the corresponding CLL and CLL-like MBL clones, according to
diagnosis.
Diagnostic subgroups
No. of cases MBLlo MBLhi CLL Other B-CLPD
Subjects Monoclonal 129 13 (87%) 25 (76%) 91 (80%) –
Multiclonal 37{ 2 (13%)* 8 (23%)* 23 (20%)* 4 (100%)*
Total 166 15 33 114 4
B-cell clones From monoclonal cases 129 13 (48%) 25 (49%) 91 (78%) –
From multiclonal cases 66 14 (52%) 26 (51%) 26 (22%) –
Total 195 27 51 117 –
*For multiclonal CLL and CLL-like MBL cases as well as for other B-CLPD cases other than CLL, only CLL-like clones were considered; the later B-CLPD cases included the
following diagnoses: HCL, hairy cell leukemia; SMZL/MALT, splenic marginal zone B-cell lymphoma/extranodal marginal zone B-cell lymphoma of mucosa-associated
lymphoid tissue lymphoma. CLL, chronic lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis; B-CLPD, B-cell chronic lymphoproliferative disorders.
{The number of clones per multiclonal case was of two in all diagnostic subgroups, except in three tri-clonal subjects corresponding to one CLL patient, one MBLhi case
and one patient with a B-CLPD other than CLL.
doi:10.1371/journal.pone.0067751.t001
IGHV and iFISH Patterns in MBL vs. CLL
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NOTCH1 mutations occurred in 5/52 CLL cases (10%), in
which a preferential association with IGHV unmutated clones
(80%, P= 0.02) and a high frequency of cases (3/5, 60%)
harbouring trisomy 12 as an additional isolated chromosomal
abnormality (P= 0.007) was observed; in the remaining two CLL
cases, the presence of NOTCH1 mutation was associated with
del(13q14) involving the RB1 gene and to both del(13q14.3) and
del(17p), respectively. None of the 19 MBL cases investigated
showed NOTCH1 mutations.
Molecular Characteristics of CLL-like MBL and CLL B-cell
Clones
Analysis of the IGHV gene revealed single in frame gene
rearrangements for each clonal B-cell population analyzed.
Interestingly, shorter CDR3 sequences of the IGHV gene were
found among MBLlo versus CLL clones. So, the frequency of CLL
clones with CDR3 sequences coding for .20 aminoacids became
significantly higher than that observed among MBLlo and MBLhi
clones (P= 0.02) (Table 4).
Regarding IGHV, DH and JH gene usage, no significant
differences were found between the three groups of CLL-like B-
Table 2. Peripheral blood (PB) B-cell counts and BCR features of clonal MBLlo, MBLhi andCLL B cells.
MBLlo
N=27
MBLhi
N=51
CLL
N=117 P value
No. of PB clonal B cells(6106/L)* 20 (0. 09–200) 2,000 (350–4,900) 17,400 (1,300{–369,000) P,0.0001a,b,c,d,e
% of PB clonal B cells from WBC* 0.6% (0.001%–7.5%) 14% (0.7%–45%) 57% (17%–97%) P,0.0001a,b,c,d,e
No. of B-cell clones from multiclonal cases 14/27 (52%) 26/51 (51%) 26/117(22%) P#0.002a,b,d;P= 0.03e
No. of IGHV mutated clones 18/27 (67%) 37/51 (73%) 60/113 (53%) P#0.02a,d
Results expressed as number of B-cell clones and percentage between brackets or as *median value (range). Statistically significant differences (P,0.05) found between
aMBLhi vs CLL, bMBLlo vs CLL, cMBLlo vs MBLhi, dMBLlo plus MBLhi vs CLL and eMBLlo vs MBLhi plus CLL. BCR, B-cell receptor; CLL, chronic lymphocytic leukemia; MBL,
monoclonal B-cell lymphocytosis; SmIg, surface membrane immunoglobulin; IGHV, immunoglobulin heavy chain variable region genes.
{Includes 6/117 cases with,5,000 clonal CLL B-cells/mL of PB, diagnosed with small lymphocytic lymphoma (SLL).
doi:10.1371/journal.pone.0067751.t002
Table 3. Cytogenetic and molecular features of MBLlo, MBLhi and CLL B-cell clones.
Cytogenetic/molecular alterations
MBLlo
N=27
MBLhi
N=51
CLL
N=117 P value
No. of genetically altered CLL-like/CLL clones 9/27 (33%) 26/51 (51%) 72/117 (62%) P#0.02b,e
No. of clones with $2 genetic alterations 2/27 (7%) 7/51 (14%) 38/117 (33%){ P#0.04a,b,d
Type of cytogenetic/molecular changes
No. of del(13q)+ clones (%)
% del(13q)+cells *
7/27 (26%)
73% (19%–96%)
16/51 (31%)
56% (15%–99%)
46/117 (39%)
87% (10%–99%)
NS
NS
No. of del(13q14.3)+ clones (%)
% del(13q14.3)+cells *
5/27 (19%)
70% (19%–96%)
16/51 (31%)
46% (15%–99%)
45/117 (39%)
75% (5%–99%)
NS
NS
No. of del(13q14)+ clones (%)
% del(13q14)+cells *
1/26 (4%)
86% (86%–86%)
3/51 (6%)
96% (15%–98%)
18/117 (15%)
79% (10%–99%)
P=0.04d
NS
No. of trisomy 12+ clones (%)
% trisomy 12+ cells *
2/27 (7%)
50% (41%–59%)
10/51 (20%)
87% (66%–95%)
20/117 (17%)
77% (33%–97%)
NS
P#0.04b,e
No. of t(14q32)+ clones (%)
% t(14q32)+ cells *
0/17 (0%)
–
2/51 (4%)
42% (31%–52%)
12/116 (10%)
82% (18%–98%)
NS
NS
No. of del(11q)+ clones (%)
% del(11q)+cells *
0/23 (0%)
–
2/51 (4%)
57% (20%–93%)
9/116 (8%)
58% (21%–98%)
NS
NS
No. of del(11q22.3)+ clones (%)
% del(11q22.3)+cells *
0/23 (0%)
–
2/51 (4%)
57% (20%–93%)
7/116 (6%)
71% (24%–98%)
NS
NS
No. of del(11q23)+ clones (%)
% del(11q23)+cells *
0/15 (0%)
–
0/51 (0%)
–
4/116 (3%)
32% (21%–64%)
NS
–
No. of del(17p13.1)+ clones (%)
% del(17p13.1)+cells *
0/24 (0%)
–
0/51 (0%)
–
5/117 (4%)
44% (33%–88%)
NS
–
No. of NOTCH1 mutated clones (%) 0/5 (0%) 0/14 (0%) 5/52 (10%) NS
Results expressed as number of B-cell clones with cytogenetic abnormalities from all clones in the corresponding group (percentage) or as *median values of altered
cells/clone (range). In 9 clones (1 MBLlo,1MBLhi and 7 CLL) biallelic del(13q14.3) was detected and hyperdiploidy was found in one MBLlo clone. aMBLhi vs CLL, bMBLlo vs
CLL, dMBLlo plus MBLhi vs CLL and eMBLlo vs MBLhi plus CLL. NS, no statistically significant differences observed (P$0.05); CLL, chronic lymphocytic leukemia; MBL,
monoclonal B-cell lymphocytosis.{Includes the 5/66 cases with NOTCH1 mutation associated to trisomy 12 in 3 cases, to biallelicdel(13q14.3) in one and to both
monoallelic del(13q14.3) and del(17p) in the remaining cases.
doi:10.1371/journal.pone.0067751.t003
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cell clones, except for the VH3 and DH3 IGHV genes (Table 4):
CLL showed lower frequency of VH3 usage and a greater
proportion of DH3+clones vs MBLlo and MBLhi (P#0.04)
(Table 4). Of note, a significant percentage of all CLL (72%),
MBLhi (74%) and MBLlo (85%) clones corresponded to only 12
IGHV genes, namely V3-23, V3-11, V5-51, V3-21, V1-2, V1-3,
V4-39, V3-7, V3-30, V4-34, V3-48 and V1-69 (Figure 1). Among
these, preferential usage (P,0.04) of the VH3-23 gene was
observed in both MBLlo (7/27, 26%) and MBLhi (10/51, 20%) vs
CLL (5/113, 4%) clones.
Relationship between the Most Frequently used IGHV
Genes and the Cytogenetic Profile of CLL-like MBL and
CLL B-cell Clones
As mentioned above, preferential usage of the VH3-23 gene was
observed in both MBLlo and MBLhi versus CLL clones (Figure 1A).
VH3-23+ MBL clones typically showed no cytogenetic alterations
(8/17) or they carried an isolated cytogenetic alteration which
corresponded either to trisomy 12 (3/17) or deletion of 13q (3/17)
(Figure 1B). Nevertheless, two MBLhi clones showed co-existence
of trisomy 12 and del(11q22.3) and one MBLlo clone showed
del(13q) including both the 13q14.3 and 13q14 (RB1) chromo-
somal regions (Figure 1B). From the fiveVH3-23+ CLL clones only
one carried genetic alterations –trisomy 12 and del(13q) –. Most
interestingly, VH3-23+MBLlo clones frequently showed unmu-
tated IGHV genes, including most unmutated MBLlo clones, with
,10 CLL-like cells/ml(5/8; 63%), which contrasts to the much
lower frequency of unmutated VH3-23 CLL clones.
A similar frequency of usage of the VH3-11, VH5-51, VH3-21
and VH1-2 genes was observed in both MBLlo and MBLhi versus
CLL (Figure 1). In none of the clones expressing these IGHV
genes, cytogenetic alterations associated with a poor disease
outcome – e.g. del(17p) and/or del(11q) – were found; in addition,
most MBL and CLL clones expressing these IGHV genes showed
no cytogenetic alteration, or they just had a single abnormality.
Despite this, NOTCH1 mutations were more frequently observed
among cytogenetically altered, IGHV unmutated CLL clones
expressing these IGHV genes (one VH3-11+, one VH3-21+ and
one VH1-2+ clones). Noteworthy, 4/6 CLL cases classified as
small lymphocytic lymphoma (SLL) variants were also included
among cases with a VH3-11 (n = 2), VH3-21 (n = 1) and VH1-2
(n = 1) repertoire in this group.
Finally, among those clonal B-cell populations which expressed
the VH1-3, VH4-39, VH3-7, VH3-30, VH4-34, VH3-48 and
VH1-69 genes, CLL clones were overrepresented (61/113, 54%)
versus both MBLlo (10/27, 37%) and MBLhi (18/51, 35%) clones.
Notably, a high number of CLL clones carrying these IGHV genes
in association with one or more cytogenetic alterations, including
poor prognosis cytogenetic alterations, was found among these
cases (44/61, 72%). In this regard, del(13q) including both the
13q14.3 and 13q14 (RB1) chromosomal regions was frequently
detected (single or combined lesion) in these CLL and also MBLhi
clones, particularly among those cases expressing the VH3-30 and
VH4-34 gene genes; presence of trisomy 12, del(11q) and t(14q32)
were also common among these CLL cases (16%, 13% and 18%,
respectively) while being infrequent in MBL cases (only 2 MBLhi
clones showed isolated trisomy 12). Moreover, del(17p) alone and
complex karyotypes with $3 cytogenetic/molecular alterations
were also found in 4 of the CLL clones which expressed the VH1-
3, VH4-39, VH3-30, VH3-48, VH4-34 and VH1-69 IGH genes,
respectively (Figure 1B). Remarkably, $1 genetic alteration was
systematically detected in a major fraction of the VH1-69+ clonal
cells (Figure 1A) while being absent in the few MBL clones which
expressed this specific IGHV gene. Of note, unmutated IGHV
genes were a hallmark of both VH1-69+ (12/14 clones; 86%) and
VH4-39+ (9/10 clones; 90%), independently of their MBL vs CLL
nature (Figure 1A).
Based on the observation of the above described associations,
we performed a multivariate analysis based on PCA, in searching
for unique patterns of association between cytogenetic alterations
and IGHV repertoires among MBL vs CLL clones. Three major
groups of CLL-like MBL and CLL clones were identified,
according to the absolute number of clonal B cells/mL and the
percentage of cells carrying cytogenetic alterations (Figure 2) and
then labelled according to their pattern of IGHV gene usage and
the VH mutational status. Of note, the most homogeneous group
(Group 1) included virtually all MBLlo clones (77%) and half of the
MBLhi clones (54%), but only around one fourth of Binet stage B/
C CLL (28%); by contrast, no MBLlo clones were included in
Group 3 (Figure 2D). Group 2 showed a more heterogeneous
distribution with an intermediate pattern. In detail, Group 1 was
mainly characterized by cases with a normal karyotype (83%) and
lower numbers of cytogenetically altered cells mostly displaying the
VH1-2, VH3-23 and VH4-34 IGHV genes (Table S2); in turn,
Group 2 typically showed a higher number of cases with mutated
IGHV genes, and higher numbers of del(13q)+ clonal B cells, while
Group 3 included high numbers of cases with unmutated IGHV
genes, trisomy 12 and an IGHV repertoire enriched in unmutated
VH1-69+ CLL clones (Table S2).
Table 4. Molecular characteristicsof the BCR of CLL-like
MBLlo, MBLhi and CLL B-cell clones.
MBLlo
N=27
MBLhi
N=51
CLL
N=113 P value
HCDR3 length* 13 (6–22) 17 (8–26) 18 (8–32) P#0.02b,d,e
HCDR3.20 aa 3/27 (11%) 8/51 (16%) 38/113 (34%) P=0.02a,b,d
VH subgroups
VH1
4/27 (15%) 7/51 (15%) 28/113 (25%) NS
VH2 0/27 (0%) 1/51 (2%) 2/113 (2%) NS
VH3 18/27 (66%) 31/51 (60%) 47/113 (42%) P#0.04a,b,d
VH4 4/27 (15%) 9/51 (17%) 32/113 (28%) NS
VH5 1/27 (4%) 3/51 (6%) 2/113 (2%) NS
VH6 0/27 (0%) 0/51 (0%) 1/113 (1%) NS
DH subgroups
DH1,4,7
5/27 (18.5%) 7/50 (14%) 15/109 (14%) NS
DH2 5/27 (18.5%) 12/50 (24%) 19/109 (17%) NS
DH3 5/27 (18.5%) 16/50 (32%) 48/109 (44%) P#0.03b,d,e
DH5 5/27 (18.5%) 8/50 (16%) 12/109 (11%) NS
DH6 7/27 (26%) 7/50 (14%) 15/109 (14%) NS
JH genes
JH1,2,3,5
4/27 (15%) 14/50 (28%) 23/113 (20%) NS
JH4 13/27 (48%) 21/50 (42%) 45/113 (40%) NS
JH6 10/27 (37%) 15/50 (30%) 45/113 (40%) NS
Results expressed as number of B-cell clones from all clones in the
corresponding group (percentage) or or as *median (range). Statistically
significant differences were found between aMBLhi vs CLL, bMBLlo vs CLL, cMBLlo
vs MBLhi, d MBLlo plus MBLhi vs CLL and eMBLlo vs MBLhi plus CLL; NS, no
statistically significant differences observed (P$0.05);BCR, B-cell receptor; CLL,
chronic lymphocytic leukemia; MBL, monoclonal B-cell lymphocytosis; aa,
aminoacids; HCDR3,heavy chain complementarity-determining region 3.
doi:10.1371/journal.pone.0067751.t004
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Discussion
It is now well established that emergence of CLL is typically
preceded by MBL [5]. However, only a fraction of all MBLhi will
evolve to CLL, at a rate of 1.1% persons/year [19], while the
outcome of MBLlo remains unknown. Despite this, general
consensus exists in that stepwise acquisition of specific genetic
alterations may determine the rate of progression, not only from
MBLhi to CLL, but potentially also from MBLlo to MBLhi and
eventually to CLL. Concurrence of chronic antigen stimulation
through specific BCRs may further support and accelerate the
expansion of MBL clones, facilitate acquisition of new genetic
alterations and therefore contribute to progression to CLL [6,20].
Although data has accumulated in the last decade about the
cytogenetic alterations and the IGHV gene repertoire of CLL-like
clonal B-cells in both MBL and CLL, to our knowledge, this is the
first report about the combined patterns of cytogenetic alterations
and IGHV gene repertoire in MBLlo vs MBLhi vs CLL clones.
Figure 1. Frequency of CLL-associated cytogenetic alterations (A) and the cytogenetic profile (B) for those IGHV genes most
commonly detected in ‘‘low-count MBL’’(MBLlo), ‘‘high-count MBL’’ (MBLhi) and CLL B-cell clones, as assessed by interphase
fluorescence in situ hybridization (iFISH). The three diagnostic categories studied are depicted by different colors (green, MBLlo; red, MBLhi;
blue, CLL B-cell clones) and the absence vs presence of one vs$2 chromosomal alterationsperclone, is indicated by empty circles, light colored and
dark colored circles, respectively. For each IGHV subgroup, the clones are represented in the Y-axis according to the absolute number of clonal B cells
per mL of PB (A) and the percentage of cells genetically altered, by iFISH (B). Different FISH patterns are defined by the following symbols in panel B:,
del(13q14.3);, biallelic del(13q14.3);, del(13q14);, trisomy 12; D, del(11q);,,del(17p) and;%, t(14q32); dotted contour lines in panel A highlight those
clones phenotypically classified as SLL(small lymphocytic lymphoma); dotted blue lines in panel B indicate cells from the same B-cell clone showing
different cytogenetic abnormalities; U = unmutated clones; a = clones with NOTCH1 mutation.
doi:10.1371/journal.pone.0067751.g001
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In recent years, more than a thousand different molecular/
genetic alterations reflected in multiple distinct and complex
cytogenetic/molecular profiles in individual CLL patients, have
been described through high-throughput whole-genome sequenc-
ing approaches [21,22]. However, only a relatively small number
of cytogenetic/molecular alterations recurrently occur at relatively
high frequencies (e.g..5% cases) [23,24]. Such alterations include
del(13q14), reported in around half of all CLL cases, trisomy 12,
present in about one third of the patients and del(11q), del(17p),
t(14q32) and NOTCH1 mutations, which occur in between 5-15%
of all CLL cases [14,23,24]. In around half of CLL cases,
unmutated IGH genes associated with preferential usage of
specific IGHV genes (i.e. VH1-69 and VH4-34) and the above
described cytogenetic alterations have also been reported in CLL.
In turn, MBLhi cases share molecular features with good-prognosis
CLL in terms of both the IGHV gene repertoire and chromosomal
alterations [25,26], with a greater frequency of IGHV mutated
cases. By contrast, preliminary data indicates that the IGHV
Figure 2. Principal component analysis (3-dimensionalX-Y-Z axis view of PC1 vs PC2 vs PC3, respectively) for comparison of ‘‘low-
count MBL’’ (MBLlo), ‘‘high-count MBL’’ (MBLhi) and CLL B-cell clones according to the absolute number of clonal B cells/mL and the
pattern of cytogenetic alterations (including the percentage of altered cells), using the InfinicytTMsoftware. Overall, MBLlo, MBLhi and
CLL cases are clustered into groups distinguished by different colors in A: magenta, gray, and black circles (A). The distribution of MBLlo, MBLhi, CLL-
stage A and CLL-stage B/C clones are coloured differently in B: MBLlo, green; MBLhi, red, CLL stage A and B/C light blue and dark blue, respectively (B).
The most informative parameters contributing to the best discrimination between 161 comparisons of the three groups are displayed in a
decreasing order of percentage contribution to each of the principal component (C); Distribution of MBLlo, MBLhi and CLL clones among the three
major groups defined in panel A by principal component analysis (D); CLL, chronic lymphocytic leukemia; MBL, monoclonal B lymphocytosis; PC:
principal component.
doi:10.1371/journal.pone.0067751.g002
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repertoire expressed by MBLlo could be strikingly different from
that of both typical CLL and MBLhi cases [27]; in addition, such
MBLlo clones appear to display a much lower frequency of
chromosomal alterations, restricted to del(13q14.3) and trisomy
12, with a high prevalence of IGHV mutated cases (similar to that
of MBLhi cases) [6], and no poor-prognosis cytogenetic alterations
[8,25].
In line with such observations, we also found a lower frequency of
both cytogenetically altered and IGHV unmutated CLL-like clones
in MBLlo vs both MBLhi and CLL and vs CLL clones, respectively.
Interestingly, the proportion of B-cell clones carrying$2 alterations
significantly increased from MBLhi to CLL. On top of the
progressively higher number of cytogenetic/molecular alterations
found in MBLlo vs MBLhi and CLL, the cytogenetic profile of clonal
B-cells also became significantly more heterogeneous among the
latter two groups. Accordingly, while del(13q14.3) and to a much
lesser extent, del(13q14) involving the RB1 gene and trisomy 12,
were already detected in a small fraction of MBLlo clones, del(11q)
and t(14q32) emerged at an MBLhi stage, whereas del(17p),
del(11q23) and NOTCH1 mutations were only found in CLL.
These latter three alterations typically involved CLL clones that
already had other cytogenetic alterations and therefore, had more
complex cytogenetic/molecular profiles. In line with these findings,
the altered CLL-like MBL and CLL clones showed progressively
increasing percentages of cells carrying del(13q14.3), del(13q14),
trisomy 12, t(14q32),del(11q)and del(17p13.1),respectively. In
accordance with previous observations [28], NOTCH1 mutations
were exclusively detected in CLL (preferentially among unmutated
CLL clones) which also had other cytogenetic alterations – e.g.,
trisomy 12, del(13q14) and/or del(17p).
The overall increased frequency of all cytogenetic alterations,
together with the more complex cytogenetic/molecular profiles,
observed from MBLlo to MBLhi and CLL would support the
notion that evolution from MBLlo to MBLhi and CLL is paralleled
by progressive acquisition of recurrent cytogenetic alterations,
each of which appears to emerge at specific MBL and CLL stages,
in line with previous data from our and other groups [12,29].
Accordingly, del(13q), and to a lesser extent trisomy 12, are
relatively early cytogenetic events which may frequently occur at
an MBLlo stage, whereas del(17p), NOTCH1 mutations, and to a
lesser extent also del(11q) and t(14q32), would typically arise later,
as secondary cytogenetic events occurring at an MBLhi or CLL
stage. Acquisition of these and other genetic changes may
potentially be associated with an increased proliferation and/or
survival of the altered CLL-like cells. At the earliest stages of
development of MBL, proliferation and/or survival signals could
be provided to the MBL clone by chronically sustained BCR
stimulation. If this holds true, the BCR features could also play a
critical role in determining the probability of cytogenetic
progression. Unfortunately, our series of MBL -particularly of
MBLlo- is quite short at this time to further confirm this
hypothesis, due to the difficulty in collecting cases with enough
number of CLL-like B-cells, to perform in parallel reliable iFISH
and molecular analyses. In this regard, the limited number of
MBLlo cases included in our series may predominantly present
with the genetic/molecular patterns of a low risk MBL cohort,
which may not be related to CLL progression. Despite this, in
accordance with other recent reports [1,30,31], non-random usage
of IGHV genes with clearly different IGHV gene repertoires was
found in our series in MBL vs CLL. As expected, the most
frequently used IGHV genes in CLL were the VH4-34, VH3-30,
VH1-69, VH3-48, VH4-39, VH1-2 and VH3-7 genes, accounting
for around half of the CLL clones. Interestingly, also half of the
CLL clones showed unmutated IGHV genes, strikingly high
frequencies of unmutated clones being detected among cells
expressing VH1-69, VH4-39 and VH1-2. By contrast, VH3-23+
B-cells predominated among the MBLlo and MBLhi clones, most
VH3-23+ MBLlo cases showing very low counts of IGHV
unmutated clonal B-cells. Of note, the IGHV genes used by the
MBLhi clones were commonly observed in either CLL (e.g. VH4–
34, VH1-2, VH3–48, and VH4–39) or MBLlo (e.g. VH3-23 and
VH4-34), but usually at lower frequencies. The fact that these
particular IGHV genes have been associated with previously
reported stereotypic B-cell receptors in CLL clones [32], together
with our own results which show that the complementary-
determining regions (CDR3) of the IGHV genes are highly
homologous in around one fifth of the B-cell clones from our short
cohort (Table S3), would reinforce the role of some antigen-
binding BCR specificities in clonal evolution.
Based on the overall patterns of cytogenetic alterations and
IGHV gene usage together with the BCR mutational status, it could
be concluded that while some unmutated IGHV genes appear to be
associated with the acquisition of complex cytogenetic profiles, rapid
expansion of clonal CLL-like B-cells and progression to CLL (e.g.
IGHV1-69), others would not (e.g. IGHV3-23); the latter clones
would show a more benign behaviour. This could potentially be due
to a lower binding affinity of the unmutated BCR for the antigen,
the recognition of specific subtypes of low concentrated antigens
and/or unique immune response profiles. In line with this
hypothesis, IGHV genes over-represented among CLL clones
(e.g.VH4-39 and VH1-69) frequently corresponded to IGHV genes
enriched in genes encoding for antibodies that recognise a broad
variety of relatively common and abundant (auto)antigens, includ-
ing low-affinity BCR, e.g. myoglobulin, thyroglobulin, actin, and
ssDNA [33,34] associated with T-independent, type II autoimmune
responses [35]. In contrast, the unmutated IGHV3-23 BCR was
over-represented among our MBLlo cases, normal peripheral blood
IGHV3-23+ IgM+ B-cells being associated with recognition of
superantigens [36–38]. Thus, the association between MBLlo and
unmutated IGHV3-23 could be potentially due to a low affinity of
this particular BCR for low concentrated/prevalent (super)antigens,
which would limit the development of repetitive immune responses
associated with the expansion of MBL clones and/or their
cytogenetic progression. A recent study [8] also reported MBLlo
cases to display an IGHV gene repertoire different from that of CLL
patients (e.g. absence of IGHV1-69+ MBLlo clones, together with a
low frequency of the IGHV4-34 gene and overrepresentation of the
IGHV4-59/61 genes); however, no preferential usage of the
IGHV3-23 gene was found among MBLlo cells in this series.
Further studies investigating the IGHV gene repertoire of MBLlo
clones in distinct geographic areas and microenvironments, may
shed light on those factors accounting for such apparent discrep-
ancies, as an association between MBLlo and previous history of
infections has been recently reported in this setting [39].
Taken together, these results would support the notion that
antigen-driven BCR-stimulation could be a triggering factor in
driving CLL-like B-cells to expand, in line with recent data
showing a significant association between MBL in the general
population and the individual history of infectious diseases and
vaccination [39], whilst depending on the nature of the antigenic
stimuli, distinct patterns of cytogenetic changes might then occur.
Thus, the specific combination of cytogenetic alterations acquired
by the CLL-like B-cells may determine, for distinct antigenic
stimuli, and specific BCR repertoires, the outcome of the
genetically-targeted cell. Long-term longitudinal studies, ideally
of the same cases at different time-points and at different stages of
the disease, would be crucial to definitively confirm these
hypotheses, although based on our preliminary follow-up date
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[40] this may require decades due to the stable nature of most
MBLlo clones in the short-term.
In summary, MBL and CLL clones appear to display a distinct
but partially overlapping pattern of IGHV gene usage, IGHV
mutational status and cytogenetic alterations, which may translate
into distinct groups of clones with different genetic/molecular
features associated with a distinct clinical behavior. Sequential
studies in larger series of cases followed for long periods of time are
ongoing to investigate the risk of progression and outcome of MBL
clones with specific IGHV and iFISH cytogenetic profiles.
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